Evidence map›Paper›PMID 39522051›Full record

ArticleStem cell research & therapy2024

Identifying and optimizing critical process parameters for large-scale manufacturing of iPSC derived insulin-producing β-cells.

Haneen Yehya, Alexandra Wells, Michael Majcher, Dhruv Nakhwa, Ryan King, Faruk Senturk, Roshan Padmanabhan, Jan Jensen, Michael A Bukys

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haneen YehyaTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Alexandra WellsTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Michael MajcherTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Dhruv NakhwaTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Ryan KingTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Faruk SenturkTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Roshan PadmanabhanTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Jan JensenTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA.
Michael A BukysTrailhead Biosystems, 23215 Commerce Park, Beachwood, OH, 44122, USA. mbukys@trailbio.com.ORCID 0009-0003-8089-1711

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 1 diabetes, an autoimmune disorder leading to the destruction of pancreatic β-cells, requires lifelong insulin therapy. Islet transplantation offers a promising solution but faces challenges such as limited availability and the need for immunosuppression. Induced pluripotent stem cells (iPSCs) provide a potential alternative source of functional β-cells and have the capability for large-scale production. However, current differentiation protocols, predominantly conducted in hybrid or 2D settings, lack scalability and optimal conditions for suspension culture.

methodsWe examined a range of bioreactor scaleup process parameters and quality target product profiles that might affect the differentiation process. This investigation was conducted using an optimized High Dimensional Design of Experiments (HD-DoE) protocol designed for scalability and implemented in 0.5L (PBS-0.5 Mini) vertical wheel bioreactors.

resultsA three stage suspension manufacturing process is developed, transitioning from adherent to suspension culture, with TB2 media supporting iPSC growth during scaling. Stage-wise optimization approaches and extended differentiation times are used to enhance marker expression and maturation of iPSC-derived islet-like clusters. Continuous bioreactor runs were used to study nutrient and growth limitations and impact on differentiation. The continuous bioreactors were compared to a Control media change bioreactor showing metabolic shifts and a more β-cell-like differentiation profile. Cryopreserved aggregates harvested from the runs were recovered and showed maintenance of viability and insulin secretion capacity post-recovery, indicating their potential for storage and future transplantation therapies.

conclusionThis study demonstrated that stage time increase and limited media replenishing with lactate accumulation can increase the differentiation capacity of insulin producing cells cultured in a large-scale suspension environment.

Indexed as

BioreactorsCell DifferentiationInduced Pluripotent Stem CellsInsulin-Secreting CellsCell Culture TechniquesCells, CulturedHumansInsulinInsulinBioprocess developmentBioreactorDiabetesDoEHuman induced pluripotent stem cellInsulin producing cellsiPSCsIsletsOptimizationPancreatic cellsβ-cells

Identifiers

PMID39522051
PMCPMC11550522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.